UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Definitions, End Points, and Clinical Trial Designs for Non-Muscle-Invasive Bladder Cancer: Recommendations From the International Bladder Cancer Group

Journal of clinical oncology, 2016-06, Vol.34 (16), p.1935-1944

2016

Volltextzugriff (PDF)

Bacillus Calmette‐Guérin immunotherapy for genitourinary cancer

BJU international, 2013-08, Vol.112 (3), p.288-297

2013

Volltextzugriff (PDF)

A First in Human Phase 1 Study of CG0070, a GM-CSF Expressing Oncolytic Adenovirus, for the Treatment of Nonmuscle Invasive Bladder Cancer

The Journal of urology, 2012-12, Vol.188 (6), p.2391-2397

2012

Volltextzugriff (PDF)

A BCG success story: From prevention of tuberculosis to optimal bladder cancer treatment

Vaccine, 2021-12, Vol.39 (50), p.7308-7318

2021

Volltextzugriff (PDF)

Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma

Journal for immunotherapy of cancer, 2017-08, Vol.5 (1), p.68-68, Article 68

2017

Volltextzugriff (PDF)

A phase 2 study of TMX-101, intravesical imiquimod, for the treatment of carcinoma in situ bladder cancer

Urologic oncology, 2017-02, Vol.35 (2), p.39.e1-39.e7

2017

Volltextzugriff (PDF)

Multi-Institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy for Nonmuscle Invasive Bladder Cancer

The Journal of urology, 2020-05, Vol.203 (5), p.902-909

2020

Volltextzugriff (PDF)

An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non–muscle-invasive bladder cancer: Interim results

Urologic oncology, 2018-10, Vol.36 (10), p.440-447

2018

Volltextzugriff (PDF)

Getting the Most Out of bacillus Calmette-Guérin for Treatment of Bladder Cancer

The Journal of urology, 2016, Vol.195 (1), p.7-8

Lamm, Donald L

2016

Volltextzugriff (PDF)

Risk‐adapted management of low‐grade bladder tumours: recommendations from the International Bladder Cancer Group (IBCG)

BJU international, 2020-04, Vol.125 (4), p.497-505

2020

Volltextzugriff (PDF)

Phase 1/2 Trial Results of a Large Surface Area Microparticle Docetaxel for the Treatment of High-Risk Nonmuscle-Invasive Bladder Cancer

The Journal of urology, 2022-10, Vol.208 (4), p.821-829

2022

Volltextzugriff (PDF)

DNA Based Therapy with Diphtheria Toxin-A BC-819: A Phase 2b Marker Lesion Trial in Patients with Intermediate Risk Nonmuscle Invasive Bladder Cancer

The Journal of urology, 2014-06, Vol.191 (6), p.1697-1702

2014

Volltextzugriff (PDF)

Enhanced Immunocompetence by Garlic: Role in Bladder Cancer and Other Malignancies

The Journal of nutrition, 2001-03, Vol.131 (3), p.1067S-1070S

2001

Volltextzugriff (PDF)

Intravesical Bacillus Calmette-Guerin Reduces the Risk of Progression in Patients with Superficial Bladder Cancer: A Meta-analysis of the Published Results of Randomized Clinical Trials

The Journal of urology, 2002-11, Vol.168 (5), p.1964-1970

2002

Volltextzugriff (PDF)

Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial

Nature medicine, 2024-08, Vol.30 (8), p.2216-2223

2024

Volltextzugriff (PDF)

Publisher Correction: Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial

Nature medicine, 2024-08, Vol.30 (8), p.2377-2377

2024

Volltextzugriff (PDF)

Author Correction: Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial

Nature medicine, 2024-08, Vol.30 (8), p.2372-2372

2024

Volltextzugriff (PDF)

Efficacy and Safety of Bacille Calmette-Guérin Immunotherapy in Superficial Bladder Cancer

Clinical infectious diseases, 2000-09, Vol.31 (Supplement-3), p.S86-S90

Lamm, Donald L.

2000

Volltextzugriff (PDF)

Bacillus Calmette-Guérin With or Without Interferon α-2b and Megadose Versus Recommended Daily Allowance Vitamins During Induction and Maintenance Intravesical Treatment of Nonmuscle Invasive Bladder Cancer

The Journal of urology, 2010-11, Vol.184 (5), p.1915-1919

2010

Volltextzugriff (PDF)

Contemporary oncologic outcomes of second induction course BCG in patients with nonmuscle invasive bladder cancer

Urologic oncology, 2020-01, Vol.38 (1), p.5.e9-5.e16

2020

Volltextzugriff (PDF)

Intravesical sequential gemcitabine and docetaxel versus bacillus calmette-guerin (BCG) plus interferon in patients with recurrent non-muscle invasive bladder cancer following a single induction course of BCG

Urologic oncology, 2022-01, Vol.40 (1), p.9.e1-9.e7

2022

Volltextzugriff (PDF)

Pelvic recurrence after radical cystectomy: a call to arms

BJU international, 2015-08, Vol.116 (2), p.172-173

2015

Volltextzugriff (PDF)

Erratum to: Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma

Journal for immunotherapy of cancer, 2017-09, Vol.5 (1), p.80-80, Article 80

2017

Volltextzugriff (PDF)

Superficial bladder cancer therapy

TheScientificWorld, 2004, Vol.4 Suppl 1, p.387-399

2004

Volltextzugriff (PDF)

1 – 25 von 235

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(224)
Mit Volltextzugriff
(103)

Publikationsform

Sprache

Englisch
(234)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(120)
Science & Technology
(120)
Humans
(117)
Urology & Nephrology
(84)
Male
(57)
Biological And Medical Sciences
(55)
Medical Sciences
(55)
Urinary Bladder Neoplasms - Therapy
(53)
Female
(47)
Bcg Vaccine - Therapeutic Use
(46)
Aged
(38)
Urinary Bladder Neoplasms - Pathology
(36)
Urinary Bladder Neoplasms - Drug Therapy
(35)
Carcinoma, Transitional Cell - Therapy
(34)
Immunotherapy
(33)
Administration, Intravesical
(30)
Middle Aged
(30)
Nephrology. Urinary Tract Diseases
(25)
Oncology
(25)
Carcinoma, Transitional Cell - Pathology
(24)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Definitions, End Points, and Clinical Trial Designs for Non-Muscle-Invasive Bladder Cancer: Recommendations From the International Bladder Cancer Group

Bacillus Calmette‐Guérin immunotherapy for genitourinary cancer

A First in Human Phase 1 Study of CG0070, a GM-CSF Expressing Oncolytic Adenovirus, for the Treatment of Nonmuscle Invasive Bladder Cancer

A BCG success story: From prevention of tuberculosis to optimal bladder cancer treatment

Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma

A phase 2 study of TMX-101, intravesical imiquimod, for the treatment of carcinoma in situ bladder cancer

Multi-Institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy for Nonmuscle Invasive Bladder Cancer

An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non–muscle-invasive bladder cancer: Interim results

Getting the Most Out of bacillus Calmette-Guérin for Treatment of Bladder Cancer

Risk‐adapted management of low‐grade bladder tumours: recommendations from the International Bladder Cancer Group (IBCG)

Phase 1/2 Trial Results of a Large Surface Area Microparticle Docetaxel for the Treatment of High-Risk Nonmuscle-Invasive Bladder Cancer

DNA Based Therapy with Diphtheria Toxin-A BC-819: A Phase 2b Marker Lesion Trial in Patients with Intermediate Risk Nonmuscle Invasive Bladder Cancer

Enhanced Immunocompetence by Garlic: Role in Bladder Cancer and Other Malignancies

Intravesical Bacillus Calmette-Guerin Reduces the Risk of Progression in Patients with Superficial Bladder Cancer: A Meta-analysis of the Published Results of Randomized Clinical Trials

Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial

Publisher Correction: Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial

Author Correction: Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial

Bladder-sparing Therapy for Bacillus Calmette-Guérin–unresponsive Non–muscle-invasive Bladder Cancer: International Bladder Cancer Group Recommendations for Optimal Sequencing and Patient Selection

Efficacy and Safety of Bacille Calmette-Guérin Immunotherapy in Superficial Bladder Cancer

Bacillus Calmette-Guérin With or Without Interferon α-2b and Megadose Versus Recommended Daily Allowance Vitamins During Induction and Maintenance Intravesical Treatment of Nonmuscle Invasive Bladder Cancer

Contemporary oncologic outcomes of second induction course BCG in patients with nonmuscle invasive bladder cancer

Intravesical sequential gemcitabine and docetaxel versus bacillus calmette-guerin (BCG) plus interferon in patients with recurrent non-muscle invasive bladder cancer following a single induction course of BCG

Pelvic recurrence after radical cystectomy: a call to arms

Erratum to: Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma

Superficial bladder cancer therapy

Suchergebnisse filtern